{"url":"https://whatshealthyandwhy.com/alpha-ketoglutarate/longevity-and-biological-age","path":"/alpha-ketoglutarate/longevity-and-biological-age","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/alpha-ketoglutarate/longevity-and-biological-age.json","markdown":"https://whatshealthyandwhy.com/alpha-ketoglutarate/longevity-and-biological-age.md"},"topic":{"slug":"alpha-ketoglutarate","name":"Alpha-Ketoglutarate","url":"https://whatshealthyandwhy.com/alpha-ketoglutarate"},"slug":"longevity-and-biological-age","order":1,"title":"Longevity, Cellular Energy, and Biological Age","question":"Does alpha-ketoglutarate slow aging or reverse biological age?","answer":"There is little evidence that alpha-ketoglutarate slows human aging; lifespan gains come from mice, and the first human trial was still underway in 2023.","description":"How this naturally occurring molecule from the Krebs cycle is gaining attention for slowing biological aging and extending healthspan","confidence":1,"confidenceNote":"Lifespan gains come from mice; the only human data are an uncontrolled retrospective analysis of 42 people (in a review) and a trial protocol.","evidenceSummary":{"rctCount":0,"observationalCount":1,"metaAnalysisCount":0,"totalParticipants":"~40","replicated":false,"newestStudyYear":2023},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Prioritize exercise, sleep and whole foods first; AKG is only a supportive add-on, not a replacement.","If you try it, calcium alpha-ketoglutarate is the most-studied form, at about 1 g a day; the human trial uses 1 g sustained-release [4].","Wait for results of the randomized ABLE trial before expecting an anti-aging effect [4]."],"cautions":["Mouse results often fail to translate to humans, and the one human biological-age report was uncontrolled and retrospective (42 people) [2].","No significant adverse effects have been reported, but human data are limited; it is not a substitute for medical care."],"simpleText":"Alpha-ketoglutarate (AKG) is a molecule your body makes naturally — it sits at the center of the Krebs cycle, the main energy-producing process inside every cell. The problem is that AKG levels decline significantly with age, and this decline is increasingly linked to the slowdown in cellular repair and the rise of chronic inflammation that defines aging [3]. Supplementing with AKG, particularly in a stable calcium salt form (Ca-AKG), has extended both lifespan and healthspan in animal studies, and early human research is now underway [1][2]. It is one of the more biologically plausible longevity compounds to emerge from recent aging research.","mediumText":"How Alpha-Ketoglutarate Works\n\nAKG is not a foreign compound — it is something your body produces constantly as part of normal metabolism. By middle age, circulating levels have dropped to a fraction of what they were in youth. Supplementing is essentially a way to restore a physiologically normal molecule, which helps explain its strong safety profile.\n\nEnergy Metabolism and the Krebs Cycle\n\nAKG is a key intermediate in the tricarboxylic acid (TCA) cycle, where it is converted into succinyl-CoA with the release of carbon dioxide and NADH. This step is central to how cells convert nutrients into ATP. When AKG is abundant, the cycle runs more efficiently, supporting energy-intensive processes like cell repair and immune function [3].\n\nEpigenetic Regulation\n\nOne of AKG's more striking roles is as a co-substrate for a family of enzymes called TET dioxygenases and Jumonji-domain histone demethylases. These enzymes are responsible for removing methyl groups from DNA and histones — a core mechanism of epigenetic regulation. As AKG declines with age, this demethylation activity slows, contributing to the accumulation of aberrant DNA methylation patterns that are a hallmark of biological aging. Supplementing AKG restores the substrate availability these enzymes need to keep the epigenome in a younger configuration [3][2].\n\nmTOR Inhibition\n\nAKG inhibits ATP synthase and, as a downstream consequence, suppresses mTOR — the growth-sensing pathway that, when chronically overactivated in aging, promotes cell senescence and suppresses autophagy. Inhibiting mTOR is one of the most well-validated approaches to extending lifespan in animal models, shared with drugs like rapamycin. AKG appears to achieve this through a metabolic rather than pharmacological mechanism [1][3].\n\nAnti-Inflammatory Effects\n\nChronic low-grade inflammation (\"inflammaging\") is central to aging-related disease. AKG, particularly as Ca-AKG, has been shown to induce IL-10 — an anti-inflammatory cytokine — while reducing the systemic inflammatory burden marked by TNF-α, IL-6, and other pro-inflammatory signals. In the mouse studies, frailty scores improved significantly alongside these inflammatory changes [1].\n\nBone and Connective Tissue Support\n\nAKG regulates histone methylation in bone marrow mesenchymal stem cells, promoting their osteogenic (bone-forming) potential. In aged mice, AKG administration increased bone mass and attenuated age-related bone loss, suggesting a role in maintaining skeletal integrity [5]. AKG is also a precursor to proline and hydroxyproline, both of which are essential building blocks for collagen.\n\nPractical Dosage\n\n- Form: Calcium alpha-ketoglutarate (Ca-AKG) is the most studied form; the calcium salt makes it shelf-stable and well-absorbed\n- Dose: Most research uses 1 gram per day; some protocols use 1–2 g/day\n- Safety: Ca-AKG is Generally Recognized as Safe (GRAS) by the FDA; no significant adverse effects have been reported in clinical research\n- Timing: Can be taken with or without food; no established timing advantage\n- Not a replacement for: exercise, sleep, whole foods, or other established longevity practices — best understood as a supportive intervention within a broader lifestyle\n\nSee our NAD+ page and spermidine page for other metabolite-based longevity approaches.","deepText":"Evidence Review\n\nAnimal Research: Lifespan and Healthspan in Mice\n\nThe foundational study by Asadi Shahmirzadi et al. (PMID 32877690), published in Cell Metabolism in 2020, is the most important preclinical work on AKG. The researchers supplemented middle-aged C57BL/6 mice with Ca-AKG starting at approximately 18 months of age (equivalent to late middle age in humans). Key findings:\n\n- Female mice showed a median lifespan extension of approximately 12% and a maximum lifespan extension of about 10%\n- Both male and female mice showed significant improvements in healthspan metrics, including reduced frailty scores on validated frailty indexes\n- Systemic inflammatory cytokines (TNF-α, IL-6, CXCL1) were significantly reduced\n- Collagen and hair coat quality — physical markers of aging — were measurably improved\n- Importantly, the supplement compressed morbidity: mice lived healthier for longer before dying, rather than extending the period of illness\n\nThe mechanism was attributed to ATP synthase inhibition leading to mTOR suppression, combined with reduced inflammation via IL-10 induction. This study used Ca-AKG in the diet at a dose equivalent to roughly 1–2 g/day in humans.\n\nLimitations: mouse physiology differs from human physiology; many longevity interventions that work in mice fail to translate. The result in females was stronger than in males, which may reflect differences in metabolic baseline.\n\nHuman Review: State of the Evidence\n\nGyanwali et al. (PMID 34952764), publishing in Trends in Endocrinology and Metabolism in 2022, reviewed all available evidence on AKG supplementation in humans. Their synthesis found:\n\n- Strong mechanistic data in cell and animal models\n- Early observational and pilot data in humans, primarily the Rejuvant retrospective analysis, which reported an average 8-year reduction in biological age (measured by TruAge DNA methylation clock) after an average of 7 months of supplementation in 42 individuals — though this was uncontrolled and retrospective\n- The authors identified the need for blinded, randomized controlled trials in humans as the critical next step\n- They flagged AKG's safety profile as strong relative to more aggressive longevity interventions like rapamycin\n\nThe 2022 review emphasized that AKG's epigenetic mechanism — specifically, its role as a co-factor for TET enzymes — is particularly compelling given the current understanding of DNA methylation as a driver of biological aging.\n\nComprehensive Review: Mechanisms and Multi-Species Evidence\n\nNaeini et al. (PMID 36934991), published in Experimental Gerontology in 2023, reviewed evidence across C. elegans, Drosophila, mice, and humans. Key findings:\n\n- In C. elegans, AKG supplementation extended lifespan by 50% in some experiments, acting through TOR signaling suppression\n- In Drosophila, lifespan extension was associated with improved reproductive function and stress resistance\n- In mice, both the Cell Metabolism results and additional studies confirmed healthspan benefits\n- In humans, the mechanisms converge on the same pathways seen in animal models\n- The authors concluded that AKG is one of the most biologically coherent anti-aging interventions, with the advantage that it is endogenous to human metabolism\n\nThe ABLE Trial Protocol\n\nSandalova et al., in GeroScience in 2023, described the protocol for the ABLE (Alpha-ketoglutarate supplementation and BiologicaL agE) trial, a double-blind, placebo-controlled randomized trial of calcium alpha-ketoglutarate (Ca-AKG) in humans [4]. Details:\n\n- 120 participants, ages 40–60, biologically older than their chronological age based on DNA methylation age\n- Intervention: 1 gram sustained-release Ca-AKG vs. placebo daily for 6 months, followed by 3 months of follow-up\n- Primary outcome: change in DNA methylation age from baseline to end of intervention\n- Secondary outcomes: inflammatory and metabolic blood markers, handgrip strength, leg extension strength, arterial stiffness, skin autofluorescence (a marker of advanced glycation end-products), and VO2 max\n- The authors note that including biologically older participants (elevated epigenetic age) is unique to this study\n\nThe protocol paper describes the design only and reports no results. Results from ABLE will be critical for determining whether the animal and observational human data translate to a real-world benefit in a controlled setting.\n\nBone Health: Epigenetic Mechanism in Aged Mice\n\nWang et al. (2020), published in Nature Communications, showed that AKG ameliorates age-related osteoporosis by regulating histone methylation [5]. In aged mice, administration of AKG increased bone mass and attenuated age-related bone loss. In bone marrow mesenchymal stem cells derived from aged mice, AKG ameliorated senescence-associated phenotypes and promoted proliferation, colony formation, migration and osteogenic (bone-forming) potential. Mechanistically, AKG decreased the accumulation of two histone methylation marks, H3K9me3 and H3K27me3, and subsequently upregulated BMP signaling and Nanog expression [5]. This links AKG's epigenetic role to a specific tissue-level aging outcome — age-related bone loss — in mice.\n\nOverall Evidence Assessment\n\nAKG has some of the strongest mechanistic rationale of any emerging longevity supplement. The Krebs cycle role, the epigenetic co-factor function, the mTOR-inhibiting properties, and the anti-inflammatory effects are all well-characterized in cell biology. Animal studies consistently show lifespan and healthspan benefits. Human evidence remains limited to retrospective and observational data, but the ABLE trial will provide the first rigorous human RCT data. Safety is excellent. This is a serious research area, not a fringe supplement claim — but anyone following it should wait for the randomized trial results before drawing strong conclusions about efficacy in humans.","deepTruncated":false,"references":[{"id":"1","title":"Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice","authors":"Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, Wiley CD, Gan G, Kim DE, Kasler HG, Kuehnemann C, Kaplowitz B, Bhaumik D, Riley RR, Kennedy BK, Lithgow GJ","year":2020,"journal":"Cell Metabolism","pmid":"32877690","url":"https://pubmed.ncbi.nlm.nih.gov/32877690/"},{"id":"2","title":"Alpha-Ketoglutarate dietary supplementation to improve health in humans","authors":"Gyanwali B, Lim ZX, Soh J, Lim C, Guan SP, Goh J, Maier AB, Kennedy BK","year":2022,"journal":"Trends in Endocrinology and Metabolism","pmid":"34952764","url":"https://pubmed.ncbi.nlm.nih.gov/34952764/"},{"id":"3","title":"Alpha-ketoglutarate as a potent regulator for lifespan and healthspan: Evidences and perspectives","authors":"Naeini SH, Mavaddatiyan L, Kalkhoran ZR, Taherkhani S, Talkhabi M","year":2023,"journal":"Experimental Gerontology","pmid":"36934991","url":"https://pubmed.ncbi.nlm.nih.gov/36934991/"},{"id":"4","title":"Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE) — intervention study protocol","authors":"Sandalova E, Goh J, Lim ZX, Lim ZM, Barardo D, Dorajoo R, Kennedy BK, Maier AB","year":2023,"journal":"GeroScience","pmid":"37217632","url":"https://pubmed.ncbi.nlm.nih.gov/37217632/"},{"id":"5","title":"Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations","authors":"Wang Y, Deng P, Liu Y, Wu Y, Chen Y, Guo Y, et al.","year":2020,"journal":"Nature Communications","pmid":"33154378","url":"https://pubmed.ncbi.nlm.nih.gov/33154378/"}],"wordCount":1391,"source":{"path":"src/content/topics/alpha-ketoglutarate/longevity-and-biological-age.md"},"citeAs":"“Does alpha-ketoglutarate slow aging or reverse biological age?.” What's Healthy and Why. https://whatshealthyandwhy.com/alpha-ketoglutarate/longevity-and-biological-age","notice":"General information backed by peer-reviewed research, not medical advice."}